![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The funding will be used for the development of a personalized dendritic cell/organoid-based vaccine for the treatment of patients with gastric cancer undergoing surgical resection.
Lead Product(s): Dendritic Cell-based Vaccine
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: DeGregorio Family Foundation
Deal Size: $0.5 million Upfront Cash: Undisclosed
Deal Type: Funding February 01, 2024
Details:
The patents cover the inhibition of soluble P-selectin that helps to prevent and/or reduce thrombotic events. Quercis’ lead drug candidate ISQ950AN, acts as an antithrombotic with significantly lower risk of adverse events than existing therapies.
Lead Product(s): Isoquercitrin
Therapeutic Area: Cardiology/Vascular Diseases Product Name: ISQ950AN
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Quercis Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 21, 2021